|
CORPORATE OVERVIEW
SynZyme Technologies,
LLC ("SynZyme" or the
"Company"), is a
privately held drug discovery and development Company
founded in 1998 that researches
and develops pharmaceutical candidates through Phase II clinical
trials, prior to licensing them to pharmaceutical companies for
further development, manufacturing and marketing. The Company works
closely with research collaborators at leading institutions around
world on new drug candidates based on free radical therapeutics for which its target-specific Caged
Nitric Oxide (CNO) technology are patented worldwide.
Its products
act via intervention of the formation, accumulation and damage
effects of reactive oxygen species during inadequate blood flow
events within the body. Its products have potential clinical
applications in a number of ischemic/ reperfusion/ inflammation
related diseases
cerebral-
and cardio-vascular diseases such as ischemic stroke, and
vaso-occlusive crisis in sickle cell disease.
VACNOÒ a vascular and neuroprotective drug for stroke and
vaso-occlusive crisis in sickle cell disease.
HemoZymeÒ a second-generation blood substitute with
both oxygen carrying and antioxidant activates for golden-hour
extension in hemorrhagic shock.
DermoZymeÒ
a
topical cream that can be used to treat skin disorders induced by UV
radiation.
|
